(Q43705288)

English

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

phase I clinical trial

0 references

Brian M. Wolpin

8

object named as

Brian Wolpin

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Andrew L Coveler

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Andrew H Ko

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Daniel V T Catenacci

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Daniel Von Hoff

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Carlos Becerra

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Nancy C Whiting

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jing Yang

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

18 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

319-328

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Antibody conjugate therapeutics: challenges and potential

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Stromal biology of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0343-X

21 January 2018

Identifiers

10.1007/S10637-016-0343-X

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43705288&oldid=2206214462"